Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis
| Status: | Archived |
|---|---|
| Conditions: | Lupus, Nephrology |
| Therapuetic Areas: | Immunology / Infectious Diseases, Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | July 2010 |
| End Date: | March 2012 |
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combination With Standard of Care (Mycophenolate Mofetil and Steroids)
The study aims to evaluate the safety and clinical effect of daily oral treatment with
laquinimod capsules in active lupus nephritis patients. This study will assess Laquinimod
doses of 0.5mg /day and 1 mg/day in combination with standard of care treatment
(mycophenolate mofetil and corticosteroids). Laquinimod is a novel immunomodulating drug
which is currently in advanced stages of development by Teva Pharmaceuticals Ltd. for
Multiple Sclerosis.
We found this trial at
10
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials